Compare American International Group Inc (AIG) vs 10X Genomics Inc (TXG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American International Group Inc vs 10X Genomics Inc — how do they compare? American International Group Inc trades at $80.33 (market cap $42.98B), while 10X Genomics Inc trades at $36.4 (market cap $4.80B). The key difference: American International Group Inc is far larger — about 9× 10X Genomics Inc's market cap, and American International Group Inc pays a 2.47% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| AIG | TXG | |
|---|---|---|
Market Cap | $42.98B | $4.80B |
Sector | Financials | Health |
52-Week High | $86.59 | $40.00 |
52-Week Low | $71.89 | $11.34 |
Enterprise Value | $50.68B | $4.35B |
Dividend Yield | 2.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIG trades at $81.06, up 2.1% today, showing strong momentum with three consecutive quarterly earnings beats. The stock is supported by bullish technical signals and a consensus price target of $88.13. Recent executive appointments and the acquisition of Everest Colombia signal strategic growth initiatives. Revenue stabilized around $26.8B in 2025 with net income margin improving to 11.88%.
Outlook remains positive with earnings growth and expansion in Latin America offering upside potential. Risks include catastrophe exposure and competitive pressures. Analysts are predominantly neutral with 58.5% Hold ratings, suggesting cautious optimism amid solid fundamentals.
TXG trades at $37.83, down 3.02% today, with a bullish technical setup despite recent weakness. The stock shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while maintaining strong 69.6% gross margins. Recent collaborations with Cleveland Clinic and the Proteintech acquisition enhance its multiomics capabilities. Technical indicators show strong momentum with the price above key moving averages, though RSI levels suggest potential overbought conditions near-term.
The outlook remains cautiously optimistic as TXG progresses toward profitability, with analyst consensus at $31.00 representing 18% downside risk. Key opportunities include expanding diagnostic applications and platform adoption, while risks center on continued losses, high valuation multiples, and competitive pressure in life sciences technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American International Group Inc
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.
Read more on AIG →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
